Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Effective Relationship Strategies for MSL Success with Commercial Counterparts
Summary
In this episode, Tom Caravela hosts Rob Rosti to delve into the critical dynamics between Medical Science Liaisons (MSLs) and commercial teams. Rob shares his background and highlights the significance of maintaining a balanced MSL-to-sales rep ratio. The discussion navigates the distinct roles and expectations of MSLs versus sales reps, emphasizing effective communication strategies. The episode addresses potential issues, compliance challenges, and strategies for handling non-compliance requests. Rob offers advice for new MSLs, focusing on fostering successful commercial relationships. The episode wraps up with final thoughts and a call to action for listeners.
My guest today is Robert Rosti, Senior Medical Science Liaison with TerSera Therapeutics and we discuss Effective Relationship Strategies for MSL Success with Commercial Counterparts
Rob shares…
π Typical MSL support expectations for sales reps and Managers
π Rules of the Road for MSLs vs Commercial
π Best practices for MSLs in communicating with sales counterparts
π What issues and pitfalls MSLs should look out for
π Advice for MSLs to ensure successful relationships with sales colleagues
MSL-to-sales rep ratio, Medical Science Liaisons, effective communication strategies, compliance challenges, successful commercial relationships
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary